BioSpace News Archive

MIRA Pharmaceuticals, Inc. announced that management will participate in the Opening Bell Ceremony at the Nasdaq Stock Market on Wednesday, August 9, 2023.

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the administration, transport and storage of drugs and vaccines, today announced the appointment of drug delivery and healthcare innovation veteran, Brian Bernick, MD, as Chairman of the company’s Board of Directors.

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).

Medical device maker CEFALY Technology will present findings from the TEAM study at the Military Health System Research Symposium August 14-17, 2023, in Kissimmee, FL.

Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced it received expanded CE (Conformité Européenne) mark approval under MDR European regulation for Nerivio® as dual-use therapy for both acute and preventive treatment of migraine for adults and adolescents.

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management.

The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA) (“the Company”), a pre-clinical-stage pharmaceutical development company developing a Novel synthetic THC analog.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol’s President and CEO,

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI).

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023